• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Clinical course of hormone refractory cancer of the prostate].

作者信息

Morote J, Vila J, López-Pacios M A, De Torres J A, Soler-Roselló A

机构信息

Servicio de Urología, Hospital Valle Hebrón, Barcelona.

出版信息

Actas Urol Esp. 1992 Oct;16(9):722-5.

PMID:1283286
Abstract

Analysis of the clinical progression of 61 patients with prostate cancer undergoing hormone therapy. PSA allowed early detection in 86.9% cases. In 25 patients no rescue treatment was instituted, and 36 patients were treated with estramustine phosphate resulting in decreased PSA levels in 58% and objective response in 36%. Of these, 82% showed decreased PSA levels for over six months. Survival rate was higher in respondent, treated patients and comparable in non-respondents, treated versus non treated patients.

摘要

相似文献

1
[Clinical course of hormone refractory cancer of the prostate].
Actas Urol Esp. 1992 Oct;16(9):722-5.
2
[Treatment of hormone-refractory prostate cancer with estramustine phosphate].磷酸雌莫司汀治疗激素难治性前列腺癌
Actas Urol Esp. 1991 Sep-Oct;15(5):421-4.
3
[Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate].[前列腺特异性抗原作为前列腺激素难治性癌治疗中的一种评估方法]
Actas Urol Esp. 1994 Jun;18(6):656-9.
4
Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer.激素难治性前列腺癌患者停用磷酸雌莫司汀后前列腺特异性抗原急剧下降。
Int J Urol. 2006 Jul;13(7):1019-21. doi: 10.1111/j.1442-2042.2006.01465.x.
5
Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.临床局限性前列腺癌患者在根治性前列腺切除术前行8个月新辅助雄激素剥夺治疗的生化和病理效应
J Urol. 1996 Jan;155(1):213-9.
6
Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.血清标志物作为前列腺转移性癌激素治疗后反应持续时间和患者生存的预测指标。
J Urol. 1997 Apr;157(4):1329-34.
7
Prostate specific antigen and prostatic acid phosphatase measurements for the follow-up of patients with prostate cancer.
Ann Clin Lab Sci. 1992 Jul-Aug;22(4):201-6.
8
Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.前列腺特异性抗原时代激素难治性前列腺癌患者的生存情况
J Urol. 2004 Apr;171(4):1525-8. doi: 10.1097/01.ju.0000118294.88852.cd.
9
Hormone therapy for locally advanced prostate cancer.局部晚期前列腺癌的激素治疗
J Urol. 2002 Aug;168(2):546-9.
10
Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.前列腺特异性抗原倍增时间对激素难治性前列腺癌伴骨转移患者生存的意义：56例癌症特异性死亡分析
Int J Urol. 2007 Feb;14(2):123-7. doi: 10.1111/j.1442-2042.2007.01672.x.